The forkhead transcription factor Foxo1 is a key mediator in insulin signaling pathway that controls hepatic glucose production (HGP) and pancreatic beta-cell function. Upon activation of the protein kinase Akt, insulin promotes glycogen synthesis and inhibits gluconeogenesis in the liver, reducing blood glucose. We previously demonstrated human Foxo1-Ser256, an equivalent to mouse Foxo1-Ser253, is a key phosphorylation site for insulin and Akt suppression, promoting Foxo1 nuclear export and suppressing the expression of the target gene for liver gluconeogenesis. Here we investigated the role of Foxo1-Ser253 phosphorylation in control of glucose hemostasis in vivo, by generating Foxo1-S253A/A knock-in (KI) mice, in which Foxo1-Ser253 replaced by alanine (A mutation) that blocks phosphorylation. Foxo1-S253A/A mice displayed mild increases in feeding blood glucose and insulin level, but reductions in fasting blood glucose and glucagon concentration, as well as a decrease in the ratio of the number of pancreatic α-cells/β-cells per islet. Foxo1-S253A/A mice exhibited slight increases in insulin sensitivity but barely changed glucose uptake among tissues, and an enhanced energy expenditure. Further analyses indicate that Foxo1-S253A/A enhanced Foxo1 ability and promoted the effect of glucagon on HGP. This is the first report demonstrating that Foxo1-Ser253 phosphorylation status itself is sufficient to affect HGP and glucose homeostasis, as well as regulate the synthesis of insulin and glucagon in in vivo.


H. Yan: None. Y. Wu: None. Q. Pan: None. Z. Shen: None. H. Zheng: None. M.F. White: Advisory Panel; Self; Housey Pharmaceutical Research Laboratories. Y. Sun: None. S. Guo: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at